SEC Form 4 · accession 0001104659-16-097376
Vitae Pharmaceuticals, Inc · VTAE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Arthur Fratamico
Officer — Chief Business Officer
Period of report
Feb 15, 2016
Accepted (ET)
Feb 16, 2016 · 4:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001157602
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $8.58 | Feb 15, 2016 | A | 19,250 | A | — | Feb 15, 2026 | Common Stock | 19,250 | 19,250 | D |
Explanation of responses
- F1This option shall vest with respect to 25% of the shares of stock which are subject to this option on February 15, 2017 (the "Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the Initial Vesting Date.